Streetbeat News

KVUE

Kenvue Inc.

https://www.kenvue.com

Industry

Household & Personal Products

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.

Open

23.52

Mkt cap

46B

Volume

13M

High

24.13

P/E Ratio

43.31

52-wk high

24.13

Low

23.44

Div yield

0.03

52-wk low

17.67

Over the past 3 months, 6 analysts have published their opinion on Kenvue (NYSE:KVUE) stock. The company has an average price target of $27.5, a decrease from the previous average price target of $28.50. The ratings are generally positive with 3 bullish, 2 somewhat bullish, and 1 indifferent.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 2:00 pm

JP Morgan analyst Andrea Teixeira has maintained an Overweight rating on Kenvue (NYSE:KVUE) but lowered the price target from $29 to $26.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:30 am

A significant amount of unusual options activity has been observed for Kenvue (NYSE:KVUE), with a majority of investors taking a bullish stance. Of the 11 strange trades detected, 72% were bullish and 27% were bearish. The total amount for the 2 put trades was $252,000, while the 9 call trades amounted to $967,827. Whales have been targeting a price range from $20.0 to $23.5 for Kenvue over the last 3 months. The current price of KVUE is down -2.2% at $20.18.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 4:46 pm

A whale investor has taken a bullish stance on Kenvue (NYSE:KVUE), with 66% of the investors opening trades with bullish expectations and 33% with bearish. The whale has been targeting a price range from $19.0 to $22.5 for Kenvue over the last 3 months. The price of KVUE is currently down -0.38% at $21.0. The next earnings are expected to be released in 50 days.

Portfolio Pulse from Benzinga Insights

September 19, 2023 | 7:31 pm

Kenvue's (NYSE:KVUE) short percent of float has fallen 78.25% since its last report, with 20.42 million shares sold short, which is 10.28% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. However, Kenvue's short interest as a percentage of float is higher than its peer group average of 6.58%.

Portfolio Pulse from Benzinga Insights

September 18, 2023 | 8:00 pm

Jim Cramer, on CNBC's 'Mad Money Lightning Round', gave his views on several stocks. He advised against investing in UiPath Inc. (PATH) and Roku, Inc. (ROKU) due to their lack of profitability. He recommended Abbott (ABT) over Kenvue Inc. (KVUE) and expressed a liking for Essential Utilities, Inc. (WTRG) due to its current low price. He also stated he is done with Plug Power Inc. (PLUG).

Portfolio Pulse from Lisa Levin

September 15, 2023 | 12:40 pm

A significant amount of unusual options activity has been detected for Kenvue (NYSE:KVUE), with a bearish stance being taken by a majority of investors. Of the 10 strange trades detected, 90% were bearish and 10% bullish. The total amount for puts was $182,236 and for calls was $438,909. Whales have been targeting a price range from $21.0 to $22.5 for Kenvue over the last 3 months. The price of KVUE is currently up 2.92% at $21.68.

Portfolio Pulse from Benzinga Insights

September 13, 2023 | 3:31 pm

An FDA panel has unanimously voted against the effectiveness of phenylephrine, a drug ingredient used in several leading decongestants. If the FDA follows the panel's recommendations, companies like Johnson & Johnson, Kenvue Inc, Bayer AG, GSK Plc's Haleon Plc, Procter & Gamble Company, Reckitt Benckiser Group and others may have to pull their oral medications containing phenylephrine from store shelves. This could also impact pharmacy retailers like CVS Health Inc, Walgreens Boots Alliance Inc, and Rite Aid Corp.

Portfolio Pulse from Vandana Singh

September 12, 2023 | 8:06 pm

Several companies have seen their ratings upgraded, downgraded, or initiated by various financial institutions. Upgrades include Brown-Forman Corp, Nu Holdings Ltd, Kenvue Inc, DoorDash Inc, Tenable Holdings Inc, and Tesla Inc. Downgrades include Brunswick Corp and Rent the Runway Inc. New coverage has been initiated for Itron Inc, Build-A-Bear Workshop Inc, Context Therapeutics Inc, Innovative Eyewear Inc, Mamas Creations Inc, Red Rock Resorts Inc, WEC Energy Group Inc, Forza X1 Inc, Raymond James Financial Inc, Ecovyst Inc, H.B. Fuller Co, SharkNinja Inc, and Blue Bird Corp.

Portfolio Pulse from Benzinga Insights

September 11, 2023 | 3:00 pm

Shares of Kenvue are trading higher after Deutsche Bank upgraded their rating of the stock to Buy.

Portfolio Pulse from Luke J Jacobi

September 11, 2023 | 12:18 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.